The Delhi High Court refused Novo Nordisk interim relief against Dr Reddy’s, finding that the Semaglutide species patent faces serious validity challenges in light of the earlier genus patent. The Court allowed Dr Reddy’s to continue manufacturing Semaglutide in India solely for export to non-patent jurisdictions, with no domestic sales.
Read more about Dr Reddy’s Semaglutide Exports to Continue as Court Denies Interim Relief to Novo NordiskTag: Novo Nordisk
CASE BRIEF: Novo Nordisk AS vs. Union of India & Ors.
The Delhi High Court’s decision in Novo Nordisk AS vs. Union of India addresses key procedural and substantive aspects of post grant patent opposition in India. The judgment clarifies evidentiary requirements, parties’ rights regarding Opposition Board reports, and the strict timelines under the Patents Act and Rules.
Read more about CASE BRIEF: Novo Nordisk AS vs. Union of India & Ors.A Patently Generic Win
The US Supreme Court’s decision in Caraco vs. Novo Nordisk clarifies the rights of generic drug manufacturers to challenge overly broad patent claims. This case marks a significant development for generic competition and FDA approval processes.
Read more about A Patently Generic Win